Erratum
for
Reck et al., J Clin Oncol 27 (8) 1227-1234.
Journal of Clinical Oncology, Vol 27, No 14 (May 10), 2009: pp. 2415
© 2009 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2009.23.1373
ERRATUM
The March 10, 2009, article by Reck et al, entitled, "Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL" (J Clin Oncol 27:1227–1234, 2009) contained errors.
In Table 3, the footnote for neutropenia was given as:
*Febrile neutropenia occurred in one (0.3%), two (0.6%), and two (0.6%) patients in the placebo, low-dose bevacizumab, and high-dose bevacizumab arms, respectively.
Whereas it should have been:
*Febrile neutropenia occurred in four (1%), five (2%), and seven (2%) patients in the placebo, low-dose bevacizumab, and high-dose bevacizumab arms, respectively.
The online version has been corrected in departure from the print.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
|
